BDBM194807 US10501452, Compound C::US9206167, 28::USRE48059, Compound of Example 28

SMILES O=C1NCCc2ccc(OCCCN3CCN(CC3)c3cccc4sccc34)cc12

InChI Key InChIKey=ZCVYWZZKFYUXJC-UHFFFAOYSA-N

Data  7 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 194807   

TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  1.20nM ΔG°:  -12.2kcal/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  1.20nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  2.80nM ΔG°:  -12.1kcal/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Leysen J E et al. (Leysen J E, Niemegeers C J E, Van Nueten J M and Laduron P M. [3H] Ketanserin (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  2.80nMAssay Description:5-HT2A: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-Ketanserin (final concentration 1 to 3 nM), 20 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Homo sapiens (Human))
Nhwa Pharma.

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  35.2nMAssay Description:D2:Procedures(1) The prepared membrane was applied with appropriate amount of buffer, and homogenizer was used for evenly dispersing. 15 tubes were m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistamine H1 receptor(RAT)
Nhwa Pharma.

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  138nMAssay Description:Histamine H1: (1) The prepared membrane was applied with appropriate amount of buffer, and homogenizer was used for evenly dispersing. 15 tubes were ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 7(Rattus norvegicus (rat))
Nhwa Pharma.

US Patent
LigandPNGBDBM194807(US10501452, Compound C | US9206167, 28 | USRE48059...)
Affinity DataKi:  500nMAssay Description:5-HT7: (1) The prepared membrane was applied with buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent